Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedJun 30, 2026
DataAggregated Company Financials
Companies546
  • 7D6.1%
  • 3M8.1%
  • 1Y40.6%
  • YTD11.2%

Over the last 7 days, the Biotech industry has risen 6.1%, driven by gains from AbbVie of 11%. In the same time, Spyre Therapeutics was down 10%. This means that the industry has gained 41% over the past year. As for the next few years, earnings are expected to grow by 25% per annum.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 01 Jul 2026US$1.4tUS$169.9b-US$12,066,496,190.2517.1x-116x8.2x
Fri, 29 May 2026US$1.3tUS$170.1b-US$12,178,146,127.0416.4x-106.4x7.6x
Sun, 26 Apr 2026US$1.3tUS$166.0b-US$11,982,883,986.9917.8x-108.3x7.8x
Tue, 24 Mar 2026US$1.3tUS$169.3b-US$15,186,325,229.0616.8x-82.6x7.4x
Thu, 19 Feb 2026US$1.3tUS$167.7b-US$13,423,257,739.5022.3x-99.6x8x
Sat, 17 Jan 2026US$1.2tUS$163.5b-US$15,150,330,768.7119.7x-80.7x7.5x
Mon, 15 Dec 2025US$1.2tUS$163.7b-US$15,628,369,300.4319x-78x7.4x
Wed, 12 Nov 2025US$1.1tUS$163.6b-US$16,225,216,537.5318x-70.6x7x
Fri, 10 Oct 2025US$1.1tUS$163.4b-US$18,200,527,307.9117x-63.2x7x
Sun, 07 Sep 2025US$1.1tUS$163.6b-US$18,346,659,491.1215.7x-58.4x6.5x
Tue, 05 Aug 2025US$1.0tUS$158.7b-US$20,364,165,757.0215.8x-49.8x6.4x
Thu, 03 Jul 2025US$937.9bUS$155.8b-US$23,533,754,618.3717.5x-39.9x6x
Sat, 31 May 2025US$930.3bUS$155.8b-US$23,980,169,264.9015.6x-38.8x6x
Mon, 28 Apr 2025US$783.2bUS$119.2b-US$31,074,126,492.8219.8x-25.2x6.6x
Wed, 26 Mar 2025US$838.8bUS$118.6b-US$36,983,100,341.2120.2x-22.7x7.1x
Fri, 21 Feb 2025US$857.3bUS$117.0b-US$37,500,625,878.7116.9x-22.9x7.3x
Sun, 19 Jan 2025US$947.4bUS$149.4b-US$26,286,185,460.0517.3x-36x6.3x
Tue, 17 Dec 2024US$991.6bUS$150.0b-US$26,487,519,670.8816.7x-37.4x6.6x
Thu, 14 Nov 2024US$1.1tUS$150.0b-US$27,361,732,021.4715x-39x7.1x
Sat, 12 Oct 2024US$884.5bUS$113.1b-US$36,028,289,614.5420.6x-24.6x7.8x
Mon, 09 Sep 2024US$874.9bUS$113.1b-US$35,665,603,175.3222.2x-24.5x7.7x
Wed, 07 Aug 2024US$1.2tUS$165.8b-US$32,869,773,768.9023.9x-35.3x7x
Fri, 05 Jul 2024US$1.1tUS$164.5b-US$28,070,736,754.8627.9x-39.9x6.8x
Sun, 02 Jun 2024US$1.1tUS$164.6b-US$26,677,143,877.6527.4x-42.1x6.8x
Tue, 30 Apr 2024US$1.1tUS$164.6b-US$27,374,440,770.8122.8x-39.1x6.5x
Thu, 28 Mar 2024US$1.2tUS$164.4b-US$23,823,048,661.6721.5x-49.4x7.2x
Sat, 24 Feb 2024US$1.2tUS$166.7b-US$21,620,417,137.2110.8x-54.5x7.1x
Mon, 22 Jan 2024US$1.4tUS$204.8b-US$22,505,807,764.0018.5x-63.4x7x
Wed, 20 Dec 2023US$1.4tUS$204.8b-US$22,154,151,632.0019.6x-61.2x6.6x
Fri, 17 Nov 2023US$1.2tUS$204.7b-US$22,125,754,712.0016.5x-54.7x5.9x
Sun, 15 Oct 2023US$1.3tUS$207.3b-US$13,137,172,262.0016.6x-96.4x6.1x
Tue, 12 Sep 2023US$1.3tUS$207.6b-US$12,635,687,518.0017.5x-101.7x6.2x
Thu, 10 Aug 2023US$1.3tUS$207.7b-US$12,585,104,613.0016.7x-101.4x6.1x
Sat, 08 Jul 2023US$1.1tUS$186.3b-US$16,022,507,026.0012.9x-69.1x5.9x
Price to Earnings Ratio

-69.1x


Total Market Cap: US$1.1tTotal Earnings: -US$16,022,507,026.00Total Revenue: US$186.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -59x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.9x is lower than the industry's current PS ratio of 8.2x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 3.0% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.31%
Healthcare7.10%
Biotech6.15%
Biotech6.15%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$254.3110.6%
+US$42.9b		37.0%PE125x
VRTX Vertex PharmaceuticalsUS$499.657.0%
+US$8.3b		12.2%PE29.2x
AMGN AmgenUS$360.553.9%
+US$7.3b		24.1%PE24.9x
NTRA NateraUS$272.3119.0%
+US$6.2b		61.2%PS15.6x
RVMD Revolution MedicinesUS$192.6216.2%
+US$5.7b		423.6%PB27.3x

Latest News

ZSQR
US$11.67
Z Squared
7D
-20.7%
1Y
49.6%
VRTX
US$499.65
Vertex Pharmaceuticals
7D
7.0%
1Y
12.2%
Seeking Alpha • 11h

Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech

Summary Vertex Pharmaceuticals Incorporated maintains a dominant, monopoly position in cystic fibrosis, driving highly predictable, recurring revenue and justifying its valuation premium. VRTX is leveraging its CF cash flows to expand into pain, hematology, and renal franchises, with promising catalysts in each area, notably Pove for IgAN. Non-CF franchises are gaining traction, with Journavx and Casgevy contributing to revenue growth; renal (Pove) is positioned to become a major driver post-2027. I maintain a Buy rating on VRTX, citing its wide moat, robust pipeline, pristine balance sheet, and clear sightlines to long-term market-beating returns. Read the full article on Seeking Alpha
ABBV
US$254.31
AbbVie
7D
10.6%
1Y
37.0%
EVMN
US$15.05
Evommune
7D
-33.3%
1Y
n/a
SYRE
US$90.16
Spyre Therapeutics
7D
-10.1%
1Y
502.3%
BIIB
US$216.63
Biogen
7D
9.9%
1Y
66.5%
RVMD
US$192.62
Revolution Medicines
7D
16.2%
1Y
423.6%
MRNA
US$69.70
Moderna
7D
14.3%
1Y
142.9%
Narrative Update • Jun 29

MRNA: Flu Approval Progress Will Still Limit Long Term Upside

Moderna's updated analyst price target framework reflects a modest fair value adjustment to about $44.25 per share, along with higher modeled revenue growth and profit margins and a lower future P/E multiple, as analysts factor in supportive regulatory commentary on the mRNA flu program and incremental optimism around the broader vaccine pipeline. Analyst Commentary Recent Street research around Moderna highlights a mix of optimism tied to the mRNA flu and broader vaccine pipeline, and caution around timing, clinical data gaps, and execution risk.
CAPR
US$23.80
Capricor Therapeutics
7D
-18.9%
1Y
139.7%
ROIV
US$34.73
Roivant Sciences
7D
11.1%
1Y
208.2%
SPRY
US$8.56
ARS Pharmaceuticals
7D
-14.2%
1Y
-50.9%
NTRA
US$272.31
Natera
7D
19.0%
1Y
61.2%
ARDX
US$5.23
Ardelyx
7D
-17.9%
1Y
33.4%
AMGN
US$360.55
Amgen
7D
3.9%
1Y
24.1%
Seeking Alpha • Jun 26

Amgen Continues To Perform

Summary Amgen is rated between Hold and Buy, with shares potentially slightly undervalued or fairly valued depending on free cash flow assumptions. Newer products like Repatha, Evenity, and Tezspire are driving double-digit growth, offsetting steep declines from legacy drugs Enbrel and Prolia. Management guides 2026 revenue of $37.1–$38.5B and non-GAAP EPS of $21.70–$23.10, reflecting steady but moderate growth. Balance sheet caution is warranted due to $57B in debt, though a robust pipeline and possible upside from MariTide support long-term optimism. Read the full article on Seeking Alpha
AUPH
US$16.79
Aurinia Pharmaceuticals
7D
-6.1%
1Y
124.5%
NNNN
US$13.55
Anbio Biotechnology
7D
-17.7%
1Y
-57.2%